Gravar-mail: Safety Profile, Efficacy, and Biodistribution of a Bicistronic High-Capacity Adenovirus Vector Encoding a Combined Immunostimulation and Cytotoxic Gene Therapy as a Prelude to a Phase I Clinical Trial for Glioblastoma